The drugs include Salts, Esters, derivatives etc. However, till the prices of bulk drugs are revised as per the DPCO, 1987, the bulk drug prices announced under DPCO, 1979 will continue.

Companies applying for the fixation of prices of bulk drugs either as a result of changes in the category of drugs or a drug which is price decontrolled under DPCO, 1979 becoming the price controlled under DPCO, 1987 or otherwise, may make applications to the BICP in form No. I under intimation to the Deptt. of Chemicals and Petro-Chemicals.

II. *Formulations*

All formulations covered under Third Schedule are price controlled. In case of drugs appearing under both the First and Second Schedules, the formulations dosage forms (single ingredient or combination), shall be considered as Category I formulations if they are recommended for use in the treatment of the disease under which the drug is included under First Schedule. All other formulations will be considered as Category II formulations.

In case of formulations of Scheduled bulk drugs and non-scheduled bulk drugs, the drug will be considered to be price controlled, if the scheduled bulk drug forms major therapeutic ingredient.

All combinations containing Vitamin(s) will be treated as Category II formulations.

The final authority to decide whether a formulation is a Scheduled formulation or otherwise and its Categorisation rests with the Government. For this purpose, all manufacturers/importers shall submit a list of formulations (licensed to manufacture under Drugs & Cosmetics Act) with proper classification within 45 days from the date of issue in case of existing products and 45 days from the date of grant of permission under Drugs & Cosmetics Act in case of new products.

III. *Application for price revision*

All applications for price fixation/revision and the representations submitted against the prices fixed under DPCO, 1979 stand disposed of. The prices fixed under DPCO, 1979 prevail in case the manufacturers desire to have revised prices for such formulations, they should submit fresh applications under the provisions of DPCO, 1987.

The manufacturers are free to revise the prices of non-scheduled formulations subject to following the procedure provided under Paragraph II. They are required to furnish information on cost details to the Government.

IV. *Mape*

For the purpose of regulating MAPE, the Government will grant 75 per cent for Category I formulations and 100 per cent for Category II formulations.

Price of Tetanus Antitoxin

666. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3522 given in the Rajya Sabha on 28th March, 1988 and state:

(a) whether it is a fact that Tetanus Antitoxin was under price control under DPCO, 1979;

(b) whether it is also a fact that price was not fixed by his Ministry for seven years;

(c) if so, what were the specific reasons for delay;

(d) whether it is a fact that producers have increased the prices of Tetanus Antitoxin by 200 per cent of the price recommended by BICP;

(e) what was the price recommended by BICP along with the details of the units on whose production the study was made;

(f) what was the percentage reduction of price made after the intervention of his Ministry along with the price under DPCO, 1979 present price and percentage change in each strength;

(g) whether it is a fact that Ministry of Health recommended for inclusion of Tetanus Antitoxin under category I; and

(h) if so, what are the details in this regard?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) The prices are fixed based on the recommendations of BICP.

(d) to (f) The required details, to the extent of information available, are given in the enclosed statement (*See* below).

(g) Yes, Sir.

(h) Vaccine and Sera were however excluded from price control on the recommendations of Kelkar Committee which opined that the availability of these products is more important than the price and the nature of demand is such that it is required less frequently but its non-availability is fatal.

Statement

Name & Pack Size	Price fixed under DPCO 79	Price increased	Reduced price after Govt. intervention	% change
ATS 750 IU 1 AMP . . .	2.24	7.26	5.40	—25.6
ATS 750 IU 50 AMP . . .	111.96	341.90	254.54	—25.6
ATS 1500 IU 1 AMP . . .	3.54	12.42	9 24	—25.6
ATS 1500 IU.50 AMP . . .	176.92	600.50	452.72	—24.6
ATS 10,000 IU 1 Vial . . .	18.62	65 26	48.54	—25.6
ATS 20,000 IU 1 vial . . .	36 27	127.60	94.95	—25.6
ATS 50,000 IU 1 vial . . .	88.30	312.74	232.68	—25.6

Price control in Polymixin-B-Sulphate

667. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3520 given in the Rajya Sabha on the 28th March, 1988 and state:

(a) what is the therapeutic indication for which Polymixin-B-Sulphate, Providone Iodine and Flucinolone Acetomide are used;

(b) whether it is a fact that all these therapeutic groups were covered under price control of DPCO, 1987;